Aventis, Mylan Debate Validity Of Prostate Cancer Treatment In Patent Appeal
WASHINGTON, D.C. — Mylan Laboratories Ltd. on April 24 defended a final written decision of the Patent Trial and Appeal Board, which deemed obvious various claims of an Aventis Pharma S.A....To view the full article, register now.
Already a subscriber? Click here to view full article